Soleno Financial Statements From 2010 to 2025

SLNO Stock  USD 49.63  0.29  0.59%   
Soleno Therapeutics financial statements provide useful quarterly and yearly information to potential Soleno Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Soleno Therapeutics financial statements helps investors assess Soleno Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Soleno Therapeutics' valuation are summarized below:
Market Capitalization
2.3 B
Earnings Share
(4.38)
We have found one hundred twenty available fundamental trend indicators for Soleno Therapeutics, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Soleno Therapeutics' current fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 18th of March 2025, Market Cap is likely to grow to about 1.7 B. Also, Enterprise Value is likely to grow to about 1.6 B

Soleno Therapeutics Total Revenue

(1.55 Billion)

Check Soleno Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Soleno Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 219.4 K or Selling General Administrative of 111.2 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 7.85 or Days Sales Outstanding of 139. Soleno financial statements analysis is a perfect complement when working with Soleno Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Soleno Therapeutics Correlation against competitors.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.

Soleno Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets347.5 M331 M71.1 M
Slightly volatile
Short and Long Term Debt Total2.6 MM3.5 M
Slightly volatile
Other Current Liabilities9.8 M9.3 MM
Pretty Stable
Total Current Liabilities19.7 M18.7 M8.6 M
Slightly volatile
Other Liabilities9.1 M10.2 M7.6 M
Slightly volatile
Property Plant And Equipment Net3.1 MM525.6 K
Slightly volatile
Accounts Payable9.3 M8.9 M2.3 M
Slightly volatile
Cash92.3 M87.9 M32.5 M
Slightly volatile
Non Current Assets Total38.9 M37.1 M11.5 M
Slightly volatile
Non Currrent Assets Other28.7 M27.3 M4.8 M
Slightly volatile
Cash And Short Term Investments306 M291.4 M58.6 M
Slightly volatile
Net Receivables104.6 K57.6 K103.6 K
Slightly volatile
Common Stock Total Equity96.6 K92 K40.3 K
Slightly volatile
Common Stock Shares Outstanding42.2 M40.2 M7.6 M
Slightly volatile
Liabilities And Stockholders Equity347.5 M331 M71.1 M
Slightly volatile
Non Current Liabilities Total70.5 M67.1 M21.2 M
Slightly volatile
Other Current Assets2.6 M2.5 M935.2 K
Slightly volatile
Other Stockholder Equity732.2 M697.3 M210.7 M
Slightly volatile
Total Liabilities90.2 M85.9 M29.8 M
Slightly volatile
Property Plant And Equipment Gross3.2 M3.1 M544.4 K
Slightly volatile
Total Current Assets308.6 M293.9 M59.6 M
Slightly volatile
Short Term Debt499.7 K526 K3.2 M
Slightly volatile
Common Stock32.2 K46 K25.9 K
Slightly volatile
Property Plant Equipment110.1 K180.6 K109.9 K
Slightly volatile
Capital Surpluse149.3 M262.1 M143 M
Slightly volatile
Deferred Long Term Liabilities460.8 K485.1 K7.2 M
Slightly volatile
Short and Long Term Debt81.2 K91.4 K99.6 K
Slightly volatile
Warrants6.144.55.54
Very volatile
Non Current Liabilities OtherM14.8 M5.1 M
Slightly volatile
Net Invested Capital309.7 M294.9 M68.3 M
Slightly volatile
Net Working Capital288.9 M275.1 M59.8 M
Slightly volatile
Capital Stock36.9 K46 K38.5 K
Pretty Stable
Long Term Debt Total6.4 K7.2 K7.8 K
Slightly volatile
Capital Lease Obligations3.1 MM646.9 K
Slightly volatile

Soleno Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.8 M2.3 M1.5 M
Slightly volatile
Selling General Administrative111.2 M105.9 M18.8 M
Slightly volatile
Other Operating Expenses50 M47.6 M20.1 M
Slightly volatile
Research Development82.5 M78.6 M18.4 M
Slightly volatile
Total Operating Expenses197.1 M187.7 M38 M
Slightly volatile
Selling And Marketing Expenses1.2 M2.3 M1.2 M
Slightly volatile
Preferred Stock And Other AdjustmentsM3.3 M3.6 M
Slightly volatile
Reconciled Depreciation2.1 MM1.8 M
Slightly volatile
Interest Income12.7 M12.1 M1.9 M
Slightly volatile

Soleno Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation105 M100 M13.9 M
Slightly volatile
Begin Period Cash Flow178.2 M169.7 M32.2 M
Slightly volatile
Depreciation1.3 MM1.1 M
Slightly volatile
End Period Cash Flow92.3 M87.9 M32.5 M
Slightly volatile
Issuance Of Capital Stock156.4 M149 M35.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Days Sales Outstanding139132113
Slightly volatile
Average Payables351.9 K667 K561.5 K
Slightly volatile
Capex To Depreciation0.120.130.2996
Pretty Stable
Inventory Turnover1.172.061.5846
Slightly volatile
Days Of Inventory On Hand174184316
Slightly volatile
Payables Turnover0.680.721.142
Very volatile
Average Inventory514.7 K379.7 K465.4 K
Slightly volatile
Cash Per Share6.897.25464.8559
Slightly volatile
Days Payables Outstanding289528414
Pretty Stable
Income Quality0.560.39290.6687
Pretty Stable
Intangibles To Total Assets0.01950.02060.2455
Pretty Stable
Current Ratio16.4615.67666.0633
Slightly volatile
Receivables Turnover2.712.856.9121
Slightly volatile
Capex Per Share0.00590.00620.309
Slightly volatile
Average Receivables104.8 K89.8 K98.3 K
Slightly volatile
Interest Debt Per Share0.06540.0689213
Slightly volatile
Debt To Assets0.00860.00911.3871
Slightly volatile
Operating Cycle239144198
Very volatile
Days Of Payables Outstanding289528414
Pretty Stable
Ebt Per Ebit1.641.081.515
Slightly volatile
Quick Ratio16.4615.67666.0231
Slightly volatile
Net Income Per E B T1.080.970.9854
Pretty Stable
Cash Ratio4.064.69024.3972
Slightly volatile
Days Of Inventory Outstanding174184316
Slightly volatile
Days Of Sales Outstanding139132113
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0187
Slightly volatile
Debt Ratio0.00860.00911.3871
Slightly volatile

Soleno Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.7 B1.6 B440.4 M
Slightly volatile
Enterprise Value1.6 B1.5 B412.9 M
Slightly volatile

Soleno Fundamental Market Drivers

Cash And Short Term Investments291.4 M

Soleno Upcoming Events

19th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
19th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Soleno Therapeutics Financial Statements

Soleno Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Soleno Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue4.8 MM
Cost Of Revenue1.8 M1.3 M
Revenue Per Share-3 K-2.8 K
Ebit Per Revenue 0.01  0.01 

Pair Trading with Soleno Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Soleno Stock

  0.31VINC Vincerx PharmaPairCorr
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Soleno Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soleno Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soleno Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soleno Therapeutics Stock:
Check out the analysis of Soleno Therapeutics Correlation against competitors.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.38)
Return On Assets
(0.45)
Return On Equity
(0.87)
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.